

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2017/017187 A1

(43) International Publication Date

2 February 2017 (02.02.2017)

(51) International Patent Classification:

A61K 38/19 (2006.01) *A61P 35/00* (2006.01)
A61K 45/06 (2006.01) *A61P 7/06* (2006.01)

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2016/068007

(22) International Filing Date:

28 July 2016 (28.07.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15179043.3 30 July 2015 (30.07.2015) EP

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(74) Agent: ZBM PATENTS - ZEA, BARLOCCI & MARK-VARDSEN; Pl. Catalunya, 1 2nd floor, 08002 Barcelona (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,



WO 2017/017187 A1

(54) **Title:** COLONY STIMULATING FACTOR FOR USE IN PANCREATIC OR COLON CANCER TREATMENT

(57) **Abstract:** There is provided a Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of colon or pancreatic cancer through an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF). The new use for these two recombinant proteins represents a new treatment option for two of the most frequent forms of cancer.

COLONY STIMULATING FACTOR FOR USE IN PANCREATIC OR COLON CANCER TREATMENT

The present invention provides granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor for use in the therapy of 5 two of the most widespread forms of malignancies, namely pancreatic and colon cancer. The use of these two recombinant proteins represents a new therapeutic option to treat these two diseases in the clinic.

BACKGROUND ART

10

Cancer is one of the leading causes of death in the first world. Contrary to what was perceived in the past, cancer is now taken as an umbrella term encompassing a huge diversity of conditions caused by a myriad of variables, among which genetic, infective and lifestyle associated factors stand out.

15

Because there is a huge number and diversity of pathological processes that can lead to the development of a malignancy, it is now widely recognized that each type of cancer responds favorably to certain therapeutic treatments but not to others. Remarkably, even the same type of cancer can have different therapeutic responses in different patients, depending on the detailed pattern 20 of cancer-causing mutations featured. Even more remarkably, cells from the same tumor derived from the same patient can also respond differently to disease modifying treatments depending on their clonal origin.

25

In spite of all biomedical advances and the efforts undertaken by society, public institutions and the pharmaceutical and biotech industries to tackle this disease, many malignancies still have a huge mortality rate. The war on cancer is far from being won. The heterogeneous character of this disease impairs the development of universal treatments, and so specific treatments for the different forms must be devised and developed. Currently, it is 30 estimated that the total cost involved in developing a new cancer biological therapy is on the order of 1.2 billion dollars (DiMasi JA, Grabowski HG. "Economics of new oncology drug development" J. Clin. Oncol. 2007, vol. 25, pp. 209-216). However, in spite of the great advances accomplished in the last decades, most of the treatments in use carry a heavy burden as the 35 therapeutic molecules are in most cases not selective for the cancerous cell, and so a range of toxic side effects always ensue.

Neutropenia, which is an abnormally low neutrophil count, is among the most serious and frequent chemotherapy-related side effects. Most cancer therapies are cytotoxic, impairing cancerous cell division by a range of 5 molecular mechanisms. This leads to cancer cells not being able to divide as quickly, which reverts to a therapeutic benefit. However, the rate of division for many normal cell lines which divide with high frequency in the body (such as epithelial cells or white blood cells) is also impaired by the non-selective treatments, which leads to serious side effects. Neutrophils usually represent 10 the biggest percentage of circulating white blood cells, and serve as the primary defense against infections by destroying bacteria found in the blood. Therefore, cancer patients with chemotherapy-related neutropenia are more susceptible to bacterial infections and, without prompt medical attention, these conditions can become life-threatening and deadly.

15

To compensate for the depletion of neutrophils due to cytotoxic chemotherapy, cancer patients following a chemotherapy regimen are concomitantly treated with a range of neutrophil enhancing therapies. The current standard treatment for neutropenia caused by chemotherapy is based 20 on the use of two recombinant proteins, namely Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF). They both stimulate the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils, thus compensating the neutrophil depleting properties of anti-tumor therapy and 25 avoiding unwanted infections. A range of analogs of G-CSF and GM-CSF have been approved for the treatment of chemotherapy-related neutropenia, such as Filgrastim, Pegfilgrastim, Lenograstim, Sargramostim and Molgramostim.

30

In the light of the high development costs cited above, the pharmaceutical industry is searching for innovative formulas to reduce the overall waste of resources due to attrition. In this respect, one of the current trends in order to find new therapies with contained cost is what has been termed as drug repurposing or reprofiling. This strategy is based on finding new indications 35 for already developed drugs. Because approved drugs have been taken through pre-clinical and clinical phases, their ADME properties, bioavailabilities and toxicities are known to be acceptable, and therefore most

of the barriers associated to these hurdles are, in principle, not an issue. Therefore, if a known safe drug is found a second indication, different from the one for which it was developed, it follows that its development should be much easier than that of a freshly discovered molecule for which no 5 experimental in vivo or human tests are available.

The reprofiling strategy can be used for any given drug, whether it is a small organic molecule or a recombinant protein. Among the proteins tested for repurposing in the cancer field, GM-CSF and G-CSF deserve a special 10 mention. They have been tested as chemotherapies in a range of cancers with varying degrees of success. GM-CSF has been proven to have a therapeutic effect when administered subcutaneously as a long-term therapy in melanoma patients after surgical resection (Spitler LE., et.al. "Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-simulating factor" J. Clin. Oncol. 2000, vol. 18, pp. 1614-1621). Also, it has been proven to have a therapeutic benefit in patients with 15 prostate cancer (Rini BI, et.al. "Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor" J. Urol. 2006, vol. 175, pp. 2087-2091). However, in other types of 20 malignancies, results have been disappointing. For instance, the use of GM-CSF as a monotherapy in the treatment of sarcoma did not reveal a therapeutic benefit (Carson EJ., et.al. "Phase II trial of sargramostim (yeast-derived recombinant human GM-CSF) as monotherapy for advanced 25 sarcomas" Proc. Am. Soc. Clin. Oncol. 2000, vol 18, Abstract 2219).

In the case of colon cancer, the role of GM-CSF and G-CSF seems to be detrimental as found in numerous references of the prior art. Thus, GM-CSF 30 has been linked to disease progression in human colorectal cancer (Demirci, U., et.al. "Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma?", Asian Pac. J. Cancer Prev. 2009, vol. 10, pp. 1021-1024; Mroczko B. "Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis" Clin. Chim. Acta. 2007, vol.380, pp. 208-12. Likewise, G-CSF 35 has also been linked to invasiveness and malignancy in colon cancer (Fujiwara Y. et.al. "Granulocyte colony-stimulating factor-producing ascending colon cancer as indicated by histopathological findings: report of a case."

Osaka City Med. J. 2011, vol. 57, pp. 79-84; Kim JS. et.al. "Administration of granulocyte colony-stimulating factor with radiotherapy promotes tumor growth by stimulating vascularization in tumor-bearing mice". Oncol Rep. 2015 vol. 34, pp. 147-54; Morris KT. et.al. "G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration" Br. J. Cancer 2014, vol.110, pp.1211-20. As for pancreatic cancer, the potential role of GM-CSF and G-CSF in the clinics still remains to be determined (Groblewska M. "Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients" Clin. Chem. Lab. Med. 2007, vol.45, pp. 30-4; Joshi S. "Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course" Intern. Med. 2009, vol. 48, pp. 687-91.

Because colon and pancreatic cancers are found in the top-10 in terms of incidence, accounting for a total of 694.000 and 330.000 deaths in 2012 respectively, and because they still have associated a poor prognosis in a significant percentage of cases, novel treatments for combating them are badly needed. It would be highly desirable to find new treatments for these two conditions among the current pharmacopeia.

SUMMARY OF THE INVENTION

Inventors have surprisingly found that exogenous G-CSF or GM-CSF, administered by injection as soluble active pharmaceutical ingredients, have a strong chemotherapeutic effect in colon and pancreatic cancer, that is, these two approved recombinant protein drugs are capable of slowing down the progression of cancerous cells in colon and pancreatic cancer. Remarkably, the potency is comparable to chemotherapeutic treatments currently in use such as gemcitabine.

The marked anti-tumor activity of G-CSF and GM-CSF for colon and pancreatic cancer, caused by the increased numbers of neutrophils, open up the way for repurposing these two recombinant drugs (currently in use for the treatment of neutropenia) as two new antineoplastic therapeutic options for these two forms of cancer.

It is found that the administration of either G-CSF or GM-CSF in order to induce neutrophilia in a patient, has a marked therapeutic effect for the two types of cancer claimed herein. Of note, this therapeutic effect is irrespective of whether the subject has a pharmacologically-induced neutropenia. The 5 invention is based on inducing neutrophilia in the cancer patients independently of the fact that they may or may not have neutropenia caused by the treatment of their disease with any other drugs.

Thus, a first aspect of the present invention is a Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of colon or pancreatic 10 cancer through an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF)

15 Remarkably, inventors have proven with the experimental data found herein that G-CSF and GM-CSF are effective in a variety of colon and pancreatic cancer *in vivo* models, which underlines their versatility as therapeutic drugs for these two malignancies.

20 BRIEF DESCRIPTION OF THE DRAWINGS

FIG.1. G-CSF antitumoral efficacy in Panc-1 model.

It is depicted the antitumoral efficacy of G-CSF in human pancreatic SC 25 tumors. Athymic nu/nu mice bearing Panc-1 SC tumors were daily treated with subcutaneous G-CSF injection at a dose of 10 µg/Kg, while GE was injected intraperitoneal at a dose of 80 mg/Kg two times per week during the whole experiment. Total tumor volume ($\text{mm}^3 \pm \text{SE}$) in saline (solid lines), G-CSF 10 µg/Kg (dashed lines) and GE 80 mg/kg (dotted) groups, for 48 days of 30 treatment are represented.

FIG.2. G-CSF antitumoral efficacy in MiaPaca model.

It is depicted the antitumoral efficacy of G-CSF in human pancreatic SC tumors. Athymic nu/nu mice bearing MiaPaca SC tumors were daily treated 35 with subcutaneous G-CSF injection at a dose of 10 µg/kg, while GE was injected intraperitoneal at a dose of 80 mg/Kg two times per week during the whole experiment. Total tumor volume ($\text{mm}^3 \pm \text{SE}$) in saline (solid lines), G-

CSF 10 μ g/kg (dashed lines) and GE 80 mg/kg (dotted) groups, for 37 days of treatment are represented.

FIG.3. G-CSF antitumoral efficacy in Panc02 model.

5 It is depicted the antitumoral efficacy of G-CSF in murine pancreatic SC tumors. C57BJL6 mice bearing Panc02 SC tumors were daily treated with subcutaneous G-CSF injection at a dose of 100 μ g/kg. Total tumor volume ($\text{mm}^3 \pm \text{SE}$) in saline (solid lines), G-CSF 100 μ g/kg (dashed lines) groups, for 22 days of treatment are represented.

10

FIG. 4. G-CSF antitumoral efficacy in Colon-26 model.

15 It is depicted the antitumoral efficacy of G-CSF in mouse colorectal SC tumors. BalbC mice bearing colorectal SC tumors were daily treated with subcutaneous G-CSF injection at a dose of 10 μ g/kg. Total tumor volume ($\text{mm}^3 \pm \text{SE}$) in saline (solid lines) and G-CSF10 μ g/kg (dashed lines) groups, for 18 days of treatment are represented.

FIG. 5. Tumor granulocytes in Colon-26 model.

20 Depiction of the tumor granulocyte levels, defined as a CD45+CD11b+Ly6G+ triple positive population, analyzed by flow cytometry from Colon-26 tumors treated with 10 μ g/kg of G-CSF during 5 days. Granulocytes cells from tumor are represented as a % of positive cells \pm SE.

FIG. 6. Effect of Sephadex on G-CSF antitumoral efficacy in Colon-26 model.

25 Depiction of the antitumoral efficacy of G-CSF in colorectal SC tumors. BalbC mice bearing Colon-26 SC tumors, with and without Sephadex papula, were treated daily with subcutaneous G-CSF injection at a dose of 50 μ g/kg. Total tumor volume ($\text{mm}^3 \pm \text{SE}$) of saline (circle), G-CSF 50 μ g/kg (square, abbreviated IT50), Sephadex-Saline (triangle), and Sephadex+G-CSF 50 μ g/kg (cross, abbreviated IT-Sephadex.), for 19 days of treatment are represented.

30

FIG.7. Effect of G-CSF on peripheral blood granulocytes levels in healthy immunocompetent and immunodeficient mice.

35 Depiction of the peripheral blood granulocytes levels in healthy C57BJL6 and Athymic nu/nu mice after the subcutaneous injection of a single dose of G-CSF (10 μ g/kg) in C57BJL6, and 10, 25, 50 and 100 μ g/kg of G-CSF in

Athymic nu/nu mice. Blood samples were taken at different time points and peripheral blood granulocytes levels are represented as a total number of granulocytes (GRA x10⁹/L).

5 FIG. 8. Effect of G-CSF on peripheral blood granulocytes levels in MiaPaca model.

Depiction of peripheral blood granulocytes levels in Athymic nu/nu mice bearing MiaPaca SC tumors after the subcutaneous injection of G-CSF 10, 25, 50 and 100 μ g/kg. Blood samples were taken at 1,5 hr and peripheral 10 blood granulocytes levels are represented as a total number of granulocytes (GRA 10⁹/L).

DETAILED DESCRIPTION OF THE INVENTION

15 For the sake of understanding, the following definitions are included and expected to be applied throughout description, claims and drawings.

20 The term “antineoplastic therapy” as used herein, refers to a treatment that is based on administering an anti-cancer active pharmaceutical ingredient (API), that is, a treatment where the API is given with the purpose of directly or indirectly arresting, delaying or slowing down the uncontrolled cellular growth and division of cancerous cells.

25 The term “increase in neutrophilia” as related to the use in the treatment of colon or pancreatic cancer, refers to an antineoplastic therapy whose effects are basically driven by increasing the amounts of neutrophils.

30 The term “neutrophil” as used herein, refers to neutrophil granulocytes which are the most abundant (up to 75%) type of white blood cells in mammals and are a central part of the innate immune system. They derive from stem cells in the bone marrow. Together with basophils and eosinophils, they form part of the polymorphonuclear cell family (PMNs).

35 The term “Colony Stimulating Factor” (CSF) as used herein, refers to a series of glycoproteins that bind protein receptors on hemopoietic cells, triggering a variety of intracellular signaling events that ultimately lead to proliferation and differentiation of the different hemopoietic cell lineages. The family is

composed of Macrophage-Colony Stimulating Factor (M-CSF), GM-CSF and G-CSF. When in the present invention CSF is used (being any of G-CSF, M-CSF or GM-CSF), it relates to any of the wild-type mammal, particularly human glycoproteins, as well as to any active pharmaceutical ingredients that derive from these proteins and including amino acid modifications. These amino acid modifications comprise amino acid additions due to the recombinant technology-based production process of the proteins, pegylations and glycosylations.

10 The term “soluble Colony Stimulating Factor (CSF) protein” as used herein, refers to a CSF that is administered parenterally in the form of an isolated soluble protein. This protein, when administered directly to the patient, is not conjugated covalently to any other macromolecule such as an antibody or any other therapeutic protein, nor is it 15 administered in the form of a nucleic acid, vector or otherwise, coding for the soluble CSF protein.

20 The protein Granulocyte-Colony Stimulating Factor (G-CSF) also known as Colony Stimulating Factor 3 (CSF3) or C17orf33, is a four-helix bundle structured glycoprotein that stimulates the production of granulocytes by the bone marrow. It is a member of the cytokine family produced by endothelial cells and macrophages and controls the production, differentiation, and function of two related white blood cell populations, the granulocytes and the monocytes-macrophages. The human G-CSF protein can be found in the 25 Uniprot database with the entry P09919 (version 169, last updated 29.04.2015). There are currently several active pharmaceutical ingredients which are very similar to human G-CSF, namely Filgrastim, Lenograstim, Lipegfilgrastim and Pegfilgrastim. Filgrastim differs from the natural protein in that an N-terminal methionine residue has been added to allow for its 30 expression in bacteria, as this product is produced in E.coli (and therefore is not glycosylated as it is when expressed by a eukaryote cell). Pegfilgrastim is the pegylated version of Filgrastim with increased half-life due to lower clearance. Both APIs are currently in standard use in the clinics for the treatment of chemotherapy-related neutropenia in cancer patients receiving 35 chemotherapy.

The protein Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)

also known as Colony Stimulating Factor 2 (CSF2), is a four-helix bundle structured glycoprotein that stimulates the production of granulocytes and macrophages by the bone marrow. It is a member of the cytokine family and controls the production, differentiation, and function of two related white blood 5 cell populations, the granulocytes and the monocytes-macrophages. The human GM-CSF protein can be found in the Uniprot database with the entry P04141 (version 160, last updated 27.05.2015). There are currently two active pharmaceutical ingredients based on human GM-CSF, namely Sargramostim and Molgramostim. They are both prescribed for the treatment 10 of chemotherapy-related neutropenia in cancer patients receiving chemotherapy.

15 The term "pancreatic cancer" as used herein refers both to exocrine and endocrine tumors.

20 The term "colon cancer" as used herein refers to any cancer that originates in the colon or rectum, especially adenocarcinoma, but also gastrointestinal stromal tumor (gist), squamous cell carcinoma, neuroendocrine and sarcoma of the colon

25 The term "neutrophil-increasing antineoplastic therapy" as used herein, refers to an antineoplastic therapy whose effects are basically driven by increasing the amounts of neutrophils.

30 The term "inducing neutrophilia" as used herein refers to a treatment that is given to a subject or a patient with the goal of increasing his/her neutrophil count above standard levels and sustaining it in time, irrespective of the fact that he/she might have neutropenia induced by any previous or concomitant treatment. The treatment in a human subject would lead to neutrophil counts that might be increased by a percentage from 600% to 1000%. It should be mentioned that the neutrophil count in a human adult is considered to be normal when it is approximately between 2.000 u/microliter and 7.500 u/microliter. The "induced neutrophilia" could result in neutrophil counts that are between 20.000 u/microliter and 45.000 u/microliter, and therefore, counts 35 that are clearly increased when compared to their standard values.

The term "therapeutically effective amount" as used herein, refers to the

amount of the CSF that, when administered, is sufficient to have a therapeutic effect. The particular dose administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the CSF administered, the exact route of administration, the 5 particular cancer being treated, the recipient subject, and similar considerations.

As mentioned above, a first aspect of the present invention is a Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of 10 colon or pancreatic cancer through an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF).

15 The Colony Stimulating Factor (CSF) for use as a neutrophil-increasing antineoplastic therapy in the treatment of colon or pancreatic cancer, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF) is considered also part of the 20 invention.

The invention can be reformulated as the use of a Colony Stimulating Factor (CSF) in the manufacture of a medicament comprising as active ingredient a Colony Stimulating Factor selected from the group consisting of Granulocyte 25 Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF), for the treatment of colon or pancreatic cancer through an increase in neutrophilia.

30 The invention can also be reformulated as a method of treatment of colon or pancreatic cancer through an increase in neutrophilia which comprises administering a therapeutically effective amount of a Colony Stimulating Factor (CSF) as an active ingredient wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF), to a subject in need thereof, including a human. 35

In a particular embodiment of the first aspect of the invention, the Colony

Stimulating Factor (CSF) is administered as the sole active ingredient.

In a particular embodiment of the first aspect of the invention, the Colony Stimulating Factor (CSF) is a soluble Colony Stimulating Factor protein.

5

In a particular embodiment of the first aspect of the invention, the administration of the Colony Stimulating Factor (CSF) is by injection.

10 In a particular embodiment of the first aspect of the invention, the use of the Colony Stimulating Factor is for inducing neutrophilia.

It also forms part of the invention, a Colony Stimulating Factor (CSF) for use as antineoplastic therapy in the treatment of colon or pancreatic cancer.

15 Additionally, it also forms part of the invention a Colony Stimulating Factor (CSF) for use as neutrophil-increasing antineoplastic therapy in the treatment of colon or pancreatic cancer.

20 In a particular embodiment of the first aspect of the invention, the neutrophilia is sustained for a period of time from 4 to 20 weeks.

In a particular embodiment of the first aspect of the invention, the neutrophilia is sustained for a period of time from 8 to 16 weeks.

25 In a particular embodiment of the first aspect of the invention, the soluble Colony Stimulating Factor (CSF) protein is for use in inducing neutrophilia.

In a particular embodiment of the first aspect of the invention, the colon cancer is adenocarcinoma of the colon.

30

In another particular embodiment of the first aspect of the invention, the pancreatic cancer is exocrine pancreatic cancer.

35 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is Granulocyte Macrophage Colony Stimulating Factor (GM-CSF).

In another particular embodiment of the first aspect of the invention, the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is Sargramostim or Molgramostim.

5 In another particular embodiment of the first aspect of the invention, the GM-CSF is a mammal and particularly human recombinant GM-CSF.

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is Granulocyte Colony Stimulating Factor (G-CSF).

10 In another particular embodiment of the first aspect of the invention, the Granulocyte Colony Stimulating Factor (G-CSF) is Filgrastim, Pegfilgrastim, Lenograstim and Lipegfilgrastim.

15 In another particular embodiment of the first aspect of the invention, the G-CSF is a mammal and particularly human recombinant G-CSF.

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered at a dose of between 100 and 1000 20 $\mu\text{g}/\text{day}$

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered at a dose of between 100 and 500 $\mu\text{g}/\text{day}$ for G-CSF and at a dose of between 200-800 $\mu\text{g}/\text{day}$ for GM-CSF.

25 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered at a dose of between 290 and 310 $\mu\text{g}/\text{day}$.

30 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered at a dose of 300 $\mu\text{g}/\text{day}$.

In another particular embodiment of the first aspect of the invention, the CSF is administered at a dose of 1-50 $\mu\text{g}/\text{kg}/\text{day}$.

35 In another particular embodiment of the first aspect of the invention, the CSF is administered at a dose of 5 $\mu\text{g}/\text{kg}/\text{day}$, 10 $\mu\text{g}/\text{kg}/\text{day}$, 15 $\mu\text{g}/\text{kg}/\text{day}$, 20

μg/kg/day, 25 μg/kg/day, 30 μg/kg/day, 35 μg/kg/day, 40 μg/kg/day, 45 μg/kg/day or 50 μg/kg/day.

5 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered over a period of between 6 and 16 weeks.

10 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered intermittently in a series of cycles, wherein the cycles can be from 1 to 5, each cycle of administration being interspersed with resting periods, wherein each resting period is from 1 to 12 weeks, and each cycle of administration is from 4 to 16 weeks.

15 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered over a period of 2.5 and 3.5 months.

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered over a period of 3 months.

20 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered subcutaneously, orally, intramuscularly or intravenously. This means that the administration route is selected from subcutaneous administration, oral administration, intramuscular administration and intravenous administration.

25 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered at a dose of between 100 and 500 μg/day for G-CSF and at a dose of between 200-800 μg/day for GM-CSF for a period of between 4 and 16 weeks, subcutaneously.

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered at a dose of between 1 and 50 μg/kg/day for a period of between 4 and 16 weeks, subcutaneously.

30 In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered at a dose of 300 μg/day over a

period of 3 months subcutaneously.

In another particular embodiment of the first aspect of the invention, the induced neutrophilia has a neutrophil count from 15.000 to 60.000 units/microliter.

In another particular embodiment of the first aspect of the invention, the induced neutrophilia has a neutrophil count from 15.000 to 50.000 units/microliter.

10

In another particular embodiment of the first aspect of the invention, the induced neutrophilia has a neutrophil count from 15.000 to 45.000 units/microliter.

15

In another particular embodiment of the first aspect of the invention, the induced neutrophilia has a neutrophil count from 20.000 to 40.000 units/microliter.

20

In another particular embodiment of the first aspect of the invention, the induced neutrophilia has a neutrophil count from 25.000 to 35.000 units/microliter.

25

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered as a sole chemical antineoplastic therapy, optionally in combination with radiotherapy.

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered as a combination chemical antineoplastic therapy.

30

In another particular embodiment of the first aspect of the invention, the Colony Stimulating Factor is administered simultaneously or sequentially with radiotherapy.

35

In another particular embodiment of the first aspect of the invention, the G-CSF or GM-CSF is administered separately, simultaneously or sequentially together with a compound selected from the group consisting of gemcitabine,

paclitaxel, 5-fluorouracyl, leucovorin, irinotecan, oxaliplatin, erlotinib, everolimus, mitomycin C, sunitinib or any combination thereof, for the treatment of pancreatic cancer.

5 In another particular embodiment of the first aspect of the invention, the G-CSF or GM-CSF is administered separately, simultaneously or sequentially together with a compound selected from the group consisting of gemcitabine, paclitaxel, 5-fluorouracyl, leucovorin, irinotecan, oxaliplatin, erlotinib, everolimus, mitomycin C, sunitinib or any combination thereof, for the 10 treatment of pancreatic cancer, and the administration of said compounds is optionally combined with radiotherapy.

In another particular embodiment of the first aspect of the invention, the G-CSF or GM-CSF is administered separately, simultaneously or sequentially 15 together with a compound selected from the group consisting of 5-fluorouracyl, capecitabine, leucovorin, irinotecan, oxaliplatin, cetuximab, bevacizumab, panitumumab, ziv-afiblercept, regorafenib, ramucirumab or any combination thereof, for the treatment of colon cancer.

20 In another particular embodiment of the first aspect of the invention, the G-CSF or GM-CSF is administered separately, simultaneously or sequentially together with a compound selected from the group consisting of 5-fluorouracyl, capecitabine, leucovorin, irinotecan, oxaliplatin, cetuximab, bevacizumab, panitumumab, ziv-afiblercept, regorafenib, ramucirumab or any 25 combination thereof, for the treatment of colon cancer, and the administration of said compounds is optionally combined with radiotherapy.

Throughout the description and claims the word "comprise" and variations of the word, are not intended to exclude other technical features, additives, 30 components, or steps. Furthermore, the word "comprise" and its variations encompasses the term "consisting of". Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples are provided by way of illustration, and they are not 35 intended to be limiting of the present invention. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.

EXAMPLES

A) Material and Methods

5

Cell lines

Human pancreatic adenocarcinoma cell lines, Panc-1 and MiaPaca cells and the mouse pancreatic adenocarcinoma cells Panc02, were used for pancreatic cancer efficacy studies. Murine colorectal carcinoma cell line,

10 Colon-26 cells, was used for colon cancer efficacy studies. All cell lines were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) (Lonza, Verviers, Belgium) medium supplemented with 10% Fetal Bovine Serum (FBS), 100 units penicillin/ml, 100 µg streptomycin/ ml, and an additional 2 mM glutamine (Lonza), and were kept in a humidified incubator at 37 °C, 5 % 15 CO₂ and passed every 3-4 days.

Mouse models and tumor growth studies

Animal procedures met the guidelines of European Community Directive

86/609/EEC and were approved by the Local Ethical Committee. Female 20 athymic nu/nu mice (6 weeks old, Harlan Iberica) were used to generate subcutaneous (SC) pancreatic tumors from Panc-1 and MiaPaca cell lines.

Immunocompetent models, C57BL/6 female mice (6 weeks old, Harlan Iberica) and Balb/C (6 weeks old, Harlan Iberica) were used to generate SC tumors from Panc01 and Colon-26 cell lines, respectively. All cell lines were 25 injected in the right side flank of mice at 6x10⁶/cell/mice. All animals were weighed and tumors were measured using manual caliper three times per week. SC tumor volumes were calculated according to the formula described by Attia and Weiss (Attia MA, et.al. "Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain

30 A mice infected with mammary tumor virus" Cancer Res. 1966 , vol. 26, pp, 1787-1800), V (mm³) = 0.4 x (larger diameter x smaller diameter²).

Antitumoral efficacy studies in pancreatic cancer models

To evaluate the antitumoral capacity of G-CSF in different pancreatic cancer

35 models in immunodeficient and immunocompetent mice, treatments were initiated when SC tumors reached a tumor volume ranging from 90 to 110 mm³. For G-CSF therapy, athymic nu/nu mice with Panc-1 (FIG. 1) and

MiaPaca (FIG. 2) and C57BL6 mice with Panc02 (FIG. 3) were randomly divided in Saline, G-CSF (Filgrastim – Amgen) and Gemcitabine (GE) groups. G-CSF treatment was applied subcutaneously every day during the whole experiment, while GE treatment was applied intraperitoneal two times per 5 week during the whole experiment. Details about each treatment are described in the present table:

Cell Lines	Doses Administered	
	G-CSF (μ g/Kg)	GE (mg/Kg)
MiaPaca	10	80
Panc-1	10	80
Panc02	100	

10

Antitumoral efficacy studies in colon cancer model

To evaluate the antitumoral capacity of G-CSF in murine colorectal carcinoma, immunocompetent Balb/C mice bearing Colon-26 tumors were treated when SC tumors reached a tumor volume ranging from 90 to 15 110 mm³. For G-CSF therapy, Balb/C mice were randomly divided in Saline and G-CSF groups. G-CSF treatment (Filgrastim – Amgen) was applied subcutaneously every day during the whole experiment (FIG. 4). At day 5 of the experiments, 4 animals of each treatment were sacrificed and tumors were collected. Granulocytes (GRA) cells were detected by FACS, analyzing 20 the markers of these cells: CD45+CD11b+Ly6G (FIG. 5). Details about each treatment are described in the present table:

Cell Lines	Doses Administered
	G-CSF (μ g/Kg)
Colon-26	10

25 Antitumoral studies were performed as described and animals were sacrificed according to the analysis of signs and symptoms of animal welfare dictated by local ethical guidelines for oncological experimentation studies.

Effects of Sephadex in Colon-26 model

Antitumoral experiments were carried out on immunocompetent Balb/C tumor-bearing mice treated with Sephadex. Sephadex treatments were initiated when SC Colon-26 tumors reached a tumor volume ranging from 90 to

5 110 mm³ and 0.5 mL of Sephadex 16% (Sephadex G-150, Pharmacia Fine Chemicals, Sweden) was subcutaneously injected in the left side flank of mice. Control animals included were Saline and Sephadex groups. In this experiment, G-CSF group was treated at a dose of 50 µg/Kg (Filgrastim – Amgen). There were 4 animals per group and their survival was monitored 10 daily (FIG. 6). In this model, Sephadex distracts functional granulocytes from the blood into the Sephadex papula thus abolishing G-CSF antitumoral activity.

Assessment of the peripheral blood hemogram

15 As peripheral blood is the only tissue routinely available from mice, the peripheral blood hemogram was also assessed in order to provide information about the behavior of blood cell populations after the subcutaneous injection of different G-CSF doses (Filgrastim – Amgen). The peripheral blood collected from the right femoral artery with a heparinized syringe in vacutainer 20 blood collection tubes containing EDTA (Sarstedt Microvette[®] CB 300) were immediately subjected to differential blood cell counts (red blood cells (RBCs), white blood cells (WBCs), and blood platelets (PLTs)) and measurement of blood hemoglobin concentration using a blood cell 25 differential automatic analyzer (ABACUS JUNIOR VET). The data for each experimental group were obtained from three to five mice. Inventors especially focused their attention on the distribution of granulocytes in the peripheral blood which was determined at 1,5 or 2, 6, 10 and 24 hrs after an initial dose of G-CSF subcutaneously. Peripheral blood granulocytes levels 30 were analyzed in healthy (FIG. 7), and tumor-bearing mice (FIG. 8). C57BL/6 healthy mice were injected with G-CSF 10 µg/kg and healthy athymic nu/nu mice were injected with different doses of G-CSF: 0, 10, 25, 50 and 100 µg/kg (FIG. 7). Athymic nu/nu mice bearing subcutaneous MiaPaca tumor were injected with G-CSF 10, 25, 50 and 100 µg/kg and blood was extracted at 1,5 hr (FIG. 8).

The anti-tumoral effects for colon and pancreatic cancer of the human colony stimulating factors were experimentally verified in a series of in vivo tests (G-CSF).

5 Before evaluating the antitumoral effect of G-CSF, inventors analyzed the effect of G-CSF on peripheral blood granulocyte levels in healthy immunocompetent and immunodeficient mice. After a single injection of varying doses of G-CSF (10, 25, 50 and 100 µg/Kg) in healthy animals, inventors observed a significant increase of peripheral blood granulocytes in 10 both animal models, reaching maximum levels at 6hs post-G-CSF injection. The increase of granulocyte levels at the 10 µg/Kg dose in C57BL6 mice was 2.5-fold compared to untreated animals. On the other hand, the increase of granulocyte levels in Athymic nu/nu mice was similar to C57BL6 mice. At a dose of 10 µg/Kg of G-CSF the increase of granulocyte levels was 2.5-fold 15 compared to untreated animals, whereas increases for 25, 50 and 100 µg/Kg doses were 3.5-, 3.7- and 3.5-fold, respectively (FIG. 7), confirming that the biological saturated levels were reached with doses higher than 25 µg/Kg.

20 To assess the antitumor activity of G-CSF (Filgrastim – Amgen), inventors utilized three pancreatic tumor models studies: xenografts from Panc-1, MiaPaca and Panc02 cells for which tumor progression was analyzed by measuring tumor volume. Animals from Panc-1 model were subcutaneously injected with daily doses of 10 µg/Kg of G-CSF and twice a week with 80 mg/Kg of Gemcitabine (GE) as a gold standard treatment, during 48 days of 25 treatment. Treatment with G-CSF produced a strong inhibition of tumor growth, reaching up to 90% of tumor inhibition compared to saline, similar results with gemcitabine were obtained (FIG. 1). Moreover, MiaPaca tumors treated under identical conditions as the Panc-1 model showed a significant inhibition in tumor growth (FIG. 2) 37 days after treatment. In this model, the tumor inhibition capacity reached up to 55% compared to saline. In this 30 model, inventors observed an increase in a dose response manner when the peripheral blood granulocyte levels were analyzed after the first subcutaneous injection of G-CSF at 10, 25, 50 and 100 µg/kg (FIG. 8)

35 Animals from Panc02 model were subcutaneously injected with daily doses of 100 µg/Kg of G-CSF during 20 days of treatment. Treatment with G-CSF produced less antitumoral activity compared to other human pancreatic tumor

models (as Panc-1 and MiaPaca) due to the aggressive profile characteristic of this murine tumor model. The inhibition capacity of the treatment reached around 50% of tumor inhibition compared to saline (FIG. 3).

5 To determine the therapeutic potential of G-CSF in colon cancer, inventors also evaluated the antitumoral activity in a murine colon cancer model. Immunocompetent animals bearing Colon-26 tumors were subcutaneously injected with daily doses of 10 µg/Kg of G-CSF during 18 days of treatment. Treatment with G-CSF reached up to 60% of tumor inhibition (FIG. 4) and up 10 to 70% of tumor inhibition when immunocompetent animals bearing Colon-26 tumors were subcutaneously injected with daily doses of 50 µg/Kg of G-CSF during 19 days (FIG. 6). In order to study the infiltrating immune cells, mainly neutrophils, into the Colon- 26 tumors after G-CSF, inventors performed flow cytometry studies where the expression of three antigens CD45, Ly6G and 15 CD11b was analyzed. In agreement with the antitumoral effect observed in Colon-26 tumors, the subcutaneous injection of G-CSF at 10 µg/Kg showed a significant increase of tumor-infiltrating granulocytes, defined as a CD45+CD11b+Ly6G+ triple positive population, in this model (FIG. 5). Any toxicity evidence was observed mediated by the daily use of G-CSF for long 20 time represented as a weight loss in all the tumor models studied.

In order to demonstrate that the G-CSF effect was mediated by a pro-inflammatory reaction induced by neutrophils, inventors challenged the antitumoral ability of G-CSF in Colon-26 model by injecting a solution of 15% 25 of Sephadex simultaneously. The Sephadex model has been extensively described in the literature as a technique to verify de implication of immune system in a therapeutic response (Jaganjac M., et. al. "The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma" Cancer Lett. 2008, vol. 260, pp. 180-186), stimulating mainly neutrophils. The 30 purpose of this study was to demonstrate, in an indirectly way, that the antitumor effect of G-CSF is mainly governed by the stimulation of the immune system. In fact, inventors administered a single subcutaneous high dose injection of Sephadex, causing a constant focus of inflammation 35 (thereby attracting immune cells, including those which were stimulated after the daily injections of G-CSF). In theory, if the therapeutic effect of G-CSF against tumor growth was in part due to the stimulation of immune cells, then the result would be a loss of antitumor effect for G-CSF treated animals in the

presence of Sephadex. Results obtained are in concordance with this theory, demonstrating that immune system stimulation plays a key role when G-CSF is administered (FIG. 6) in cancer therapy. Immunocompetent animals bearing Colon-26 tumors treated with daily doses of 50 µg/Kg of G-CSF 5 during 19 days, the tumor inhibition reached 70%, while the Immunocompetent animals bearing Colon-26 tumors and Sephadex and treated with daily doses of 50 µg/Kg of G-CSF during 19 days, the tumor inhibition reached 50%. Furthermore, the subcutaneous injection of Sephadex 10 induced lower neutrophils levels in peripheral blood, which are smoothly recovered after the G-CSF injection.

In summary, these results indicate that daily subcutaneous delivery of G-CSF induces strong antitumoral effects to pancreatic and colon tumors mediated by the specific recruitment of granulocytes to the tumor in these models.

15

REFERENCES CITED IN THE APPLICATION

Attia MA, Weiss DW. "Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice 20 infected with mammary tumor virus" Cancer Res. 1966, vol. 26, pp. 1787-1800.

DiMasi JA, Grabowski HG. "Economics of new oncology drug development" J. Clin. Oncol. 2007, vol. 25, pp. 209-216

Spitler LE., et.al. "Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor" J. Clin. Oncol. 2000, 25 vol. 18, pp. 1614-1621

Rini BI, et.al. "Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor" J. Urol. 2006, vol. 175, pp. 2087-2091

Carson EJ., et.al. "Phase II trial of sargramostim (yeast-derived recombinant human GM-CSF) as monotherapy for advanced sarcomas" Proc. Am. Soc. Clin. Oncol. 2000, vol 18, Abstract 2219

Demirci, U., et.al. "Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma?", Asian Pac. J. Cancer Prev. 2009, vol. 10, pp. 1021-1024

5

Fujiwara Y. et.al. "Granulocyte colony-stimulating factor-producing ascending colon cancer as indicated by histopathological findings: report of a case." Osaka City Med. J. 2011, vol. 57, pp. 79-84

10 Jaganjac M., et. al. "The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma" Cancer Lett. 2008, vol. 260, pp. 180-186

15 Mroczko B. et.al. "Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis" Clin Chim Acta. 2007, vol.380, pp.208-12.

20 Kim JS. et.al. "Administration of granulocyte colony-stimulating factor with radiotherapy promotes tumor growth by stimulating vascularization in tumor-bearing mice" Oncol Rep. 2015, vol.34, pp.147-54

Morris KT. et.al. "G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration" Br. J. Cancer 2014, vol. 110, pp. 1211-20

25

Groblewska M. et. al. "Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients" Clin. Chem. Lab. Med. 2007, vol. 45, pp.30-4.

30 Joshita S. et.al. "Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course" Intern. Med. 2009, vol.48, pp. 687-91

35

CLAIMS

5

1. A Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of colon or pancreatic cancer through an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF).

10

2. The Colony Stimulating Factor (CSF) for use as claimed in claim 1, wherein the CSF is administered as the sole active ingredient.

15

3. The Colony Stimulating Factor (CSF) for use as claimed in any of the claims 1-2, wherein the Colony Stimulating Factor is a soluble Colony Stimulating Factor protein.

20

4. The Colony Stimulating Factor (CSF) for use as claimed in any of the claims 1-3, wherein the administration of the CSF is by injection.

5. The soluble Colony Stimulating Factor (CSF) protein for use according to any one of claims 1-4, which is for use in inducing neutrophilia.

25

6. The Colony Stimulating Factor for use as claimed in any of the claims 1-5, wherein the colon cancer is adenocarcinoma of the colon.

7. The Colony Stimulating Factor for use as claimed in any of the claims 1-6, wherein the pancreatic cancer is exocrine pancreatic cancer.

30

8. The Colony Stimulating Factor for use as claimed in any of the claims 1-7, wherein the Colony Stimulating Factor is Granulocyte Macrophage Colony Stimulating Factor (GM-CSF).

35

9. The Colony Stimulating Factor for use according to claim 8, wherein the GM-CSF is Sargramostim or Molgramostim.

10. The Colony Stimulating Factor for use as claimed in any of the claims 1-7, wherein the Colony Stimulating Factor is Granulocyte Colony Stimulating Factor (G-CSF).
- 5 11. The Colony Stimulating Factor for use according to claim 10, wherein the G-CSF is Filgrastim, Pegfilgrastim, Lenograstim or Lipegfilgrastim.
- 10 12. The Colony Stimulating Factor for use as claimed in any of the claims 1-11, wherein the administration of the CSF is at a dose of between 100 and 1000 µg/day.
- 15 13. The Colony Stimulating Factor for use as claimed in any of the claims 1-12, wherein the administered doses are given over a period of between 4 and 16 weeks.
- 20 14. The Colony Stimulating Factor for use as claimed in any of the claims 1-13, wherein the administration is subcutaneous, oral, intramuscular or intravenous.
- 25 15. The Colony Stimulating Factor for use as claimed in any of the claims 1-14, wherein the administration is at a dose of between 100 and 600 µg/day for G-CSF and at a dose of between 200-800 µg/day for GM-CSF for a period of between 4 and 16 weeks, subcutaneously.
- 30 16. The Colony Stimulating Factor for use as claimed in any of the claims 1-15, wherein the induced neutrophilia has a neutrophil count from 15.000 to 45.000 units/microliter.
17. The Colony Stimulating Factor for use as claimed in any of the claims 1-30, wherein the G-CSF or GM-CSF is administered as a combination chemical antineoplastic therapy.
- 35 18. The Colony Stimulating Factor for use according to claim 17, wherein G-CSF or GM-CSF is administered separately, simultaneously or sequentially together with a compound selected from the group consisting of gemcitabine, paclitaxel, 5-fluorouracil, leucovorin, irinotecan, oxaliplatin, erlotinib, everolimus, mitomycin C, sunitinib or any combination thereof, for the

25

treatment of pancreatic cancer, and the administration of said compounds is optionally combined with radiotherapy.

19. The Colony Stimulating Factor for use according to claim 17, wherein G-
5 CSF or GM-CSF is administered separately, simultaneously or sequentially
together with a compound selected from the group consisting of 5-
fluorouracyl, capecitabine, leucovorin, irinotecan, oxaliplatin, cetuximab,
bevacizumab, panitumumab, ziv-aflibercept, regorafenib, ramucirumab or any
10 combination thereof, for the treatment of colon cancer, and the administration
of said compounds is optionally combined with radiotherapy.

15

20

25

30

35




FIG.1




FIG.2




FIG.3




FIG.4




FIG. 5




FIG.6




FIG.7




FIG.8

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/068007

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K38/19 A61K45/06 A61P35/00 A61P7/06
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010/303714 A1 (KIRN DAVID [US]) 2 December 2010 (2010-12-02)	1,4,6, 14,17-19
Y	paragraphs [0052], [0064], [0171], [0174], [0189], [0194], [0195], [0203]; claims 1, 6 -----	1,4-19
X	US 2014/227179 A1 (LIU DONGLIN [US] ET AL) 14 August 2014 (2014-08-14)	1,2,4,7, 8,14
Y	paragraphs [0166], [0191]; claims 1,3,8 -----	1-19
X	US 2013/078279 A1 (NEMUNAITIS JOHN J [US] ET AL) 28 March 2013 (2013-03-28)	1,2,4
Y	claims 1,11 ----- -/-	1-19

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search 18 November 2016	Date of mailing of the international search report 30/11/2016
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Durrenberger, Anne

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/068007

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SPITLER L E ET AL: "Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 18, no. 8, 1 April 2000 (2000-04-01), pages 1614-1621, XP009186364, ISSN: 0732-183X the whole document -----	1-19
A	HOWARD L KAUFMAN ET AL: "Current status of granulocyte?macrophage colony-stimulating factor in the immunotherapy of melanoma", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. 1, 13 May 2014 (2014-05-13), page 11, XP021189803, ISSN: 2051-1426, DOI: 10.1186/2051-1426-2-11 the whole document -----	1-19
A	RINI B I ET AL: "Clinical and Immunological Characteristics of Patients With Serologic Progression of Prostate Cancer Achieving Long-Term Disease Control With Granulocyte-Macrophage Colony-Stimulating Factor", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 175, no. 6, 1 June 2006 (2006-06-01), pages 2087-2091, XP024990748, ISSN: 0022-5347, DOI: 10.1016/S0022-5347(06)00261-8 [retrieved on 2006-06-01] cited in the application the whole document -----	1-19
A	WO 88/06452 A1 (GENETICS INST [US]) 7 September 1988 (1988-09-07) the whole document -----	1-19
X	US 2015/202268 A1 (BOCK JASON BENJAMIN [US] ET AL) 23 July 2015 (2015-07-23)	1,3-5, 8-11,14, 17-19
Y	paragraphs [0137] - [0140]; claims; table 1 -----	1-19
A	EP 2 612 676 A1 (GENERON SHANGHAI CORP LTD [CN]) 10 July 2013 (2013-07-10) the whole document -----	1-19
		-/-

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/068007

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008/122415 A1 (SANDOZ AG [CH]; FUERTINGER SABINE [AT]; MATOUS HEINRICH [AT]) 16 October 2008 (2008-10-16) the whole document -----	1-19
A	"Neutropenia in cancer patients: risk factors and management", , 1 March 2010 (2010-03-01), XP055219343, Retrieved from the Internet: URL: http://www.cancerworld.org/pdf/7580_paginga_15-22_grandround.pdf [retrieved on 2015-10-08] the whole document -----	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2016/068007

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 2010303714	A1 02-12-2010	AU 2008224811	A1 18-09-2008	BR PI0808736	A2 19-08-2014
		CA 2681096	A1 18-09-2008	CN 101790310	A 28-07-2010
		DK 2136633	T3 25-01-2016	EP 2136633	A1 30-12-2009
		ES 2559684	T3 15-02-2016	HK 1139563	A1 26-08-2016
		HR P20160041	T1 12-02-2016	JP 5879024	B2 08-03-2016
		JP 2010521497	A 24-06-2010	JP 2014193882	A 09-10-2014
		KR 20080084528	A 19-09-2008	KR 20090122293	A 26-11-2009
		KR 20150041181	A 15-04-2015	PT 2136633	E 22-02-2016
		SI 2136633	T1 31-03-2016	US 2010303714	A1 02-12-2010
		WO 2008113078	A1 18-09-2008		
<hr/>					
US 2014227179	A1 14-08-2014	US 2014227179	A1 14-08-2014	US 2015165076	A1 18-06-2015
		US 2016090413	A1 31-03-2016		
<hr/>					
US 2013078279	A1 28-03-2013	AR 081057	A1 06-06-2012	AU 2010333753	A1 19-07-2012
		CA 2785258	A1 30-06-2011	CN 102917709	A 06-02-2013
		EP 2515916	A1 31-10-2012	JP 5553906	B2 23-07-2014
		JP 5820506	B2 24-11-2015	JP 2013515731	A 09-05-2013
		JP 2014210781	A 13-11-2014	KR 20120099503	A 10-09-2012
		KR 20140108344	A 05-09-2014	SG 181880	A1 30-07-2012
		SG 188160	A1 28-03-2013	SG 10201606680Q	A 28-10-2016
		TW 201130975	A 16-09-2011	TW 201522632	A 16-06-2015
		US 2011262408	A1 27-10-2011	US 2013078279	A1 28-03-2013
		US 2015329873	A1 19-11-2015	WO 2011079077	A1 30-06-2011
<hr/>					
WO 8806452	A1 07-09-1988	DE 3875859	T2 13-05-1993	EP 0303687	A1 22-02-1989
		JP 2634218	B2 23-07-1997	JP H01502593	A 07-09-1989
		WO 8806452	A1 07-09-1988		
<hr/>					
US 2015202268	A1 23-07-2015	AU 2010204547	A1 28-07-2011	AU 2010204552	A1 04-08-2011
		CA 2749786	A1 22-07-2010	CA 2749802	A1 22-07-2010
		CN 102378635	A 14-03-2012	CN 102395379	A 28-03-2012
		EA 201190079	A1 28-02-2013		

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2016/068007

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		EA 201190080 A1	31-03-2014	
		EP 2387419 A2	23-11-2011	
		EP 2387420 A2	23-11-2011	
		JP 5753095 B2	22-07-2015	
		JP 2012515221 A	05-07-2012	
		JP 2012515222 A	05-07-2012	
		KR 20110132326 A	07-12-2011	
		KR 20110132327 A	07-12-2011	
		NZ 594055 A	28-03-2013	
		NZ 594056 A	28-03-2013	
		SG 172940 A1	29-08-2011	
		SG 172941 A1	29-08-2011	
		SG 196821 A1	13-02-2014	
		US 2010227818 A1	09-09-2010	
		US 2010297062 A1	25-11-2010	
		US 2013129669 A1	23-05-2013	
		US 2015202268 A1	23-07-2015	
		WO 2010083434 A2	22-07-2010	
		WO 2010083439 A2	22-07-2010	
<hr/>				
EP 2612676	A1	10-07-2013	CN 102380090 A	21-03-2012
			CN 103079586 A	01-05-2013
			EP 2612676 A1	10-07-2013
			EP 3028713 A1	08-06-2016
			US 2013165637 A1	27-06-2013
			US 2015147290 A1	28-05-2015
			WO 2012028093 A1	08-03-2012
<hr/>				
WO 2008122415	A1	16-10-2008	AT 493117 T	15-01-2011
			AU 2008235044 A1	16-10-2008
			CA 2679551 A1	16-10-2008
			CN 101657187 A	24-02-2010
			EP 2142174 A1	13-01-2010
			HK 1135329 A1	15-04-2011
			JP 5349452 B2	20-11-2013
			JP 2010523510 A	15-07-2010
			SI 2142174 T1	29-04-2011
			US 2010104627 A1	29-04-2010
			WO 2008122415 A1	16-10-2008
<hr/>				